Fetuin-A (AHSG) Human ELISA

Cat. No.	Size	Price
RD191037100	96 wells (1 kit)	$590

Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Urine, Cerebrospinal fluid, Cell culture supernatant

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

2–100 ng/ml

Limit of Detection

0.104 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 2.9%

Inter-assay (Run-to-Run)

n = 6; CV = 4.7%

Spiking Recovery

108,80%

Dilution Linearity

110,40%

Crossreactivity

bovine Non-detectable
cat Non-detectable
dog Non-detectable
goat Non-detectable
hamster Non-detectable
horse Non-detectable
mouse Non-detectable
pig Non-detectable
rabbit Non-detectable
rat Non-detectable
sheep Non-detectable
chicken Not tested
human Yes
monkey Yes (recommended dilution 1:5000)

Note

The kits are CE-IVD certified and intended for professional use.

Summary

Features

European Union: for in vitro diagnostic use
Rest of the world: for research use only!
The total assay time is less than 3 hours
The kit measures fetuin-A in serum and plasma (EDTA, citrate, heparin)
Assay format is 96 wells
Quality Controls are human serum based. No animal sera are used
Standard is human plasma based
Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism, Cardiovascular disease, Renal disease

Summary

Fetuin-A (AHSG), a 59 kDa glycoprotein, consists of two cystatin-like domains and a smaller
unrelated domain. Its homologues have been identified in several species including rat (pp63),
mouse, guinea pig, rabbit, sheep, cattle, swine and human. AHSG human gene is located on
chromosome 3q27.
Liver synthesized fetuin-A is secreted into the blood stream and it is deposited as a
noncollagenous protein in mineralized bones and teeth.
Fetuin-A occurs in high serum concentration during fetal life, whereas its level declines
following infection, inflammation (by 20-30% during acute phase) and malignancy. Fetuin-A
may influence the resolution of inflammation by modulating the phagocytosis of apoptotic cells
by macrophages.
Fetuin-A acts as an important circulating inhibitor of ectopic calcification that is a frequent
complication of many degenerative diseases.
The low fetuin-A level may be associated with higher cardiovascular mortality in chronic renal
failure, liver cancer and liver cirrhosis patients on long-term dialysis.
Human fetuin-A represents a natural inhibitor of tyrosine kinase activity of the insulin receptor.
Fetuin-A may play a significant role in regulating postprandial glucose disposal, insulin
sensitivity, weight gain, and fat accumulation and may be a novel therapeutic target in the
treatment of type 2 diabetes, obesity, and other insulin-resistant conditions.
The serum and bone-resident fetuin-A binds to transforming growth factor-β and blocks TGF-β
binding to cell surface receptors.
Thus, fetuin-A is involved at least in inhibition of unwanted (vascular) calcification, inhibition of insulin receptor tyrosine kinase activity and regulation of osteogenesis.

Product References (91)

References

Summary References (18)

References to Fetuin-A

Arnaud P, Kalabay L. Alpha2-HS glycoprotein: a protein in search of a function. Diabetes Metab Res Rev. 2002 Jul-Aug; 18(4): 311-4. Review.
Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003 Nov 15; 376(Pt 1): 135-45.
Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V59-66
Geroldi D, Minoretti P, Bianchi M, Di Vito C, Reino M, Bertona M, Emanuele E. Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians. Neurosci Lett. 2005 Oct 7;386 (3):176-8
Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, Jahnen-Dechent W. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003 Apr 11;278 (15):13333-41
Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006 Apr 11;113 (14):1760-7
Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond). 2003 Sep; 105(3): 273-8.
Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 Mar 8; 361(9360): 827-33.
Kundranda MN, Henderson M, Carter KJ, Gorden L, Binhazim A, Ray S, Baptiste T, Shokrani M, Leite-Browning ML, Jahnen-Dechent W, Matrisian LM, Ochieng J. The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms. Cancer Res. 2005 Jan 15;65 (2):499-506
Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, Yim CY, Kwak YG. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol. 2004 Sep;32 (9):836-42
Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979 Oct;64 (4):1118-29
Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005 Mar;67 (3):1070-7
Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet. 2005 Feb;116 (3):146-51
Osawa M, Umetsu K, Sato M, Ohki T, Yukawa N, Suzuki T, Takeichi S. Structure of the gene encoding human alpha 2-HS glycoprotein (AHSG). Gene. 1997 Sep 1;196 (1-2):121-5
Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003 Oct 21;118 (1-2):140-6
Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005 Oct;16 (10):2920-30
Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003 Aug; 112(3): 357-66.
Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. Th

By Research Topic

Bone and cartilage metabolism
Cardiovascular disease
Renal disease

By Molecule

Fetuin-A

By Technical Data

Docs

Find documents for the lot

Example Instructions for Use (RUO)

Safety Information (RUO)

MSDS (RUO)
MSDS (RUO)

Product Brochure

CE IVD Assays